17th Apr 2019 12:28
LONDON (Alliance News) - PureTech Health PLC on Wednesday said it has entered into a research collaboration with Boehringer Ingelheim to develop novel product candidates.
Under terms of the agreement, PureTech said it will receive up to USD26 million, including upfront payments, research support, and preclinical milestones, and is eligible to receive more than USD200 million in development and sales milestones, in addition to royalties on product sales.
The biopharmaceutical company said the collaboration will initially focus on applying its lymphatic targeting technology to an immuno-oncology product candidate designated by Boehringer Ingelheim.
By targeting the lymphatic system directly, PureTech said the technology has the potential to achieve more effective and precise immunomodulation of local tissues, while sparing the patient from the risks of extensive systemic exposure to the drug.
"We see great promise in leveraging PureTech's platform to target the lymphatic system and deliver therapeutic candidates directly to the lymph nodes responsible for priming, educating and proliferating immune cells," said Clive Wood, global head of discovery research at Boehringer Ingelheim.
"This collaboration signals the exciting potential of another proprietary platform from our internal R&D to enable novel immunotherapy approaches by harnessing the lymphatic system's capacity for immune cell trafficking and immunomodulation," added Daphne Zohar, co-founder & chief executive officer of PureTech.
PureTech shares were trading 2.8% higher on Wednesday at 186.80 pence each.
Related Shares:
PureTech